Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study

International Journal of Antimicrobial Agents

Volumn 29, Issue 5, 2007, Pages 557-562

  Garey, Kevin W ^a   Turpin, Robin S ^b,c   Bearden, David T ^d   Pai, Manjunath P ^e   Suda, Katie J ^f  

^a UNIVERSITY OF HOUSTON   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Candidaemia; Cohort study; Fluconazole; Hospital mortality; Multicentre study; Pharmacoeconomics

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ADULT; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CLINICAL TRIAL; COHORT ANALYSIS; DRUG COST; FEMALE; FUNGUS CULTURE; FUNGUS ISOLATION; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONEY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THERAPY DELAY; UNITED STATES;

AGED; ANTIFUNGAL AGENTS; CANDIDIASIS; COSTS AND COST ANALYSIS; FEMALE; FLUCONAZOLE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34147172440     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.01.001     Document Type: Article

References (34)

1. Antoniadou A., Torres H.A., Lewis R.E., et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 82 (2003) 309-321
2. Hajjeh R.A., Sofair A.N., Harrison L.H., et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42 (2004) 1519-1527
3. Malani A., Hmoud J., Chiu L., Carver P.L., Bielaczyc A., and Kauffman C.A. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 41 (2005) 975-981
4. Safdar A., Chaturvedi V., Cross E.W., et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 45 (2001) 2129-2133
5. Safdar A., Singhal S., and Mehta J. Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001). Cancer 100 (2004) 2456-2461
6. Tortorano A.M., Peman J., Bernhardt H., et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23 (2004) 317-322
7. Pappas P.G., Rex J.H., Sobel J.D., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
8. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 (2006) 25-31
9. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49 (2005) 3640-3645
10. Olaechea P.M., Palomar M., Leon-Gil C., et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 23 (2004) 323-330
11. Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., and Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41 (2005) 1232-1239
12. Rentz A.M., Halpern M.T., and Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 27 (1998) 781-788
13. Golan Y., Wolf M.P., Pauker S.G., Wong J.B., and Hadley S. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med 143 (2005) 857-869
14. Morgan J., Meltzer M.I., Plikaytis B.D., et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 26 (2005) 540-547
15. Wilson L.S., Reyes C.M., Stolpman M., Speckman J., Allen K., and Beney J. The direct cost and incidence of systemic fungal infections. Value Health 5 (2002) 26-34
16. Iregui M., Ward S., Sherman G., Fraser V.J., and Kollef M.H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122 (2002) 262-268
17. Leibovici L., Konisberger H., Pitlik S.D., Samra Z., and Drucker M. Patients at risk for inappropriate antibiotic treatment of bacteraemia. J Intern Med 231 (1992) 371-374
18. Micek S.T., Lloyd A.E., Ritchie D.J., Reichley R.M., Fraser V.J., and Kollef M.H. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49 (2005) 1306-1311
19. Clancy C.J., Yu V.L., Morris A.J., Snydman D.R., and Nguyen M.H. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 49 (2005) 3171-3177
20. Lee S.C., Fung C.P., Huang J.S., et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 44 (2000) 2715-2718
21. Torres H.A., Kontoyiannis D.P., and Rolston K.V. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study. Support Care Cancer 12 (2004) 511-516
22. Morgan J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 7 (2005) 429-439
23. Blumberg H.M., Jarvis W.R., Soucie J.M., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33 (2001) 177-186
24. McKinnon P.S., Goff D.A., Kern J.W., et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg 136 (2001) 1401-1408 discussion 9
25. Puzniak L., Teutsch S., Powderly W., and Polish L. Has the epidemiology of nosocomial candidemia changed?. Infect Control Hosp Epidemiol 25 (2004) 628-633
26. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., and Wenzel R.P. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 149 (1989) 2349-2353
27. von Baum H., Ober J.F., Wendt C., Wenzel R.P., and Edmond M.B. Antibiotic-resistant bloodstream infections in hospitalized patients: specific risk factors in a high-risk population?. Infection 33 (2005) 320-326
28. Piarroux R., Grenouillet F., Balvay P., et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 32 (2004) 2443-2449
29. Pittet D., Monod M., Suter P.M., Frenk E., and Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220 (1994) 751-758
30. Alexander B.D., and Pfaller M.A. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 43 (2006) S15-S27
31. Alexander B.D., Ashley E.D., Reller L.B., and Reed S.D. Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis 54 (2006) 277-282
32. Wilson D.A., Joyce M.J., Hall L.S., et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol 43 (2005) 2909-2912
33. Pfaller M.A., Diekema D.J., and Sheehan D.J. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19 (2006) 435-447
34. Vazquez J.A., and Sobel J.D. Anidulafungin: a novel echinocandin. Clin Infect Dis 43 (2006) 215-222